Issue

Vol. 13 (2021)

Correction to: Tetrahedral Framework Nucleic Acid‑Based Delivery of Resveratrol Alleviates Insulin Resistance: From Innate to Adaptive Immunity

https://doi.org/10.1007/s40820-021-00711-6
Yanjing Li
State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, People’s Republic of China
Shaojingya Gao
State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, People’s Republic of China
Sirong Shi
State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, People’s Republic of China
Dexuan Xiao
State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, People’s Republic of China
Shuanglin Peng
Department of Oral and Maxillofacial Surgery, Hospital of Stomatology, Southwest Medical University, Luzhou 646000, People’s Republic of China
Yang Gao
State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, People’s Republic of China
Ying Zhu
Zhangjiang Laboratory, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai 201210, People’s Republic of China
Yunfeng Lin
State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, People’s Republic of China

Corresponding Author: Yunfeng Lin

yunfenglin@scu.edu.cn

Nano-Micro Letters, Vol. 13 (2021), Article Number: 186

Abstract

Obesity-induced insulin resistance is the hallmark of metabolic syndrome, and chronic, low-grade tissue inflammation links obesity to insulin resistance through the activation of tissue-infiltrating immune cells. Current therapeutic approaches lack efficacy and immunomodulatory capacity. Thus, a new therapeutic approach is needed to prevent chronic inflammation and alleviate insulin resistance. Here, we synthesized a tetrahedral framework nucleic acid (tFNA) nanoparticle that carried resveratrol (RSV) to inhibit tissue inflammation and improve insulin sensitivity in obese mice. The prepared nanoparticles, namely tFNAs-RSV, possessed the characteristics of simple synthesis, stable properties, good water solubility, and superior biocompatibility. The tFNA-based delivery ameliorated the lability of RSV and enhanced its therapeutic efficacy. In high-fat diet (HFD)-fed mice, the administration of tFNAs-RSV ameliorated insulin resistance by alleviating inflammation status. tFNAs-RSV could reverse M1 phenotype macrophages in tissues to M2 phenotype macrophages. As for adaptive immunity, the prepared nanoparticles could repress the activation of Th1 and Th17 and promote Th2 and Treg, leading to the alleviation of insulin resistance. Furthermore, this study is the first to demonstrate that tFNAs, a nucleic acid material, possess immunomodulatory capacity. Collectively, our findings demonstrate that tFNAs-RSV alleviate insulin resistance and ameliorate inflammation in HFD mice, suggesting that nucleic acid materials or nucleic acid-based delivery systems may be a potential agent for the treatment of insulin resistance and obesity-related metabolic diseases.


Highlights:


1 Tetrahedral framework nucleic acid (tFNA)-based delivery of resveratrol (RSV) ameliorates the performance of RSV.
2 tFNAs-RSV improve insulin sensitivity in high-fat diet-fed mice by promoting Treg and Th2 and suppressing Th1 and Th17, and switching macrophage from M1 to M2 phenotype both in vitro and in vivo.

Keywords

Tetrahedral framework nucleic acid Resveratrol Insulin resistance Inflammation Innate immunity Adaptive immunity
Li, Yanjing, Shaojingya Gao, Sirong Shi, Dexuan Xiao, Shuanglin Peng, Yang Gao, Ying Zhu, and Yunfeng Lin. 2021. “Correction To: Tetrahedral Framework Nucleic Acid‑Based Delivery of Resveratrol Alleviates Insulin Resistance: From Innate to Adaptive Immunity”. Nano-Micro Letters 13 (September):186. https://doi.org/10.1007/s40820-021-00711-6.
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. R.H. Eckel, S.M. Grundy, P.Z. Zimmet, The metabolic syndrome. Lancet 365(9468), 1415–1428 (2005). https://doi.org/10.1016/S0140-6736(05)66378-7
  2. R.H. Eckel, K.G.M.M. Alberti, S.M. Grundy, P.Z. Zimmet, The metabolic syndrome. Lancet 375(9710), 181–183 (2010). https://doi.org/10.1016/S0140-6736(09)61794-3
  3. P. Zimmet, K.G. Alberti, J. Shaw, Global and societal implications of the diabetes epidemic. Nature 414(6865), 782–787 (2001). https://doi.org/10.1038/414782a
  4. A.M.F. Johnson, J.M. Olefsky, The origins and drivers of insulin resistance. Cell 152(4), 673–684 (2013). https://doi.org/10.1016/j.cell.2013.01.041
  5. H. Wu, C.M. Ballantyne, Metabolic Inflammation and Insulin Resistance in Obesity. Circ. Res. 126(11), 1549–1564 (2020). https://doi.org/10.1161/CIRCRESAHA.119.315896
  6. D.M. Mosser, J.P. Edwards, Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8(12), 958–969 (2008). https://doi.org/10.1038/nri2448
  7. G. Liu, H. Yang, Modulation of macrophage activation and programming in immunity. J. Cell Physiol. 228(3), 502–512 (2013). https://doi.org/10.1002/jcp.24157
  8. S.P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R.L. Leibel et al., Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest 112(12), 1796–1808 (2003). https://doi.org/10.1172/JCI19246
  9. C.N. Lumeng, J.L. Bodzin, A.R. Saltiel, Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest 117(1), 175–184 (2007). https://doi.org/10.1172/JCI29881
  10. S. Winer, Y. Chan, G. Paltser, D. Truong, H. Tsui et al., Normalization of obesity-associated insulin resistance through immunotherapy. Nat. Med. 15(8), 921–929 (2009). https://doi.org/10.1038/nm.2001
  11. H. Sell, C. Habich, J. Eckel, Adaptive immunity in obesity and insulin resistance. Nat. Rev. Endocrinol. 8(12), 709–716 (2012). https://doi.org/10.1038/nrendo.2012.114
  12. M. Feuerer, L. Herrero, D. Cipolletta, A. Naaz, J. Wong et al., Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 15(8), 930–939 (2009). https://doi.org/10.1038/nm.2002
  13. D. Cipolletta, M. Feuerer, A. Li, N. Kamei, J. Lee et al., PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 486(7404), 549–553 (2012). https://doi.org/10.1038/nature11132
  14. S. Malozowski, J.T. Sahlroot, Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 357(3), 302–303 (2007). https://doi.org/10.1056/NEJMc071324
  15. T.L. Stanley, M.V. Zanni, S. Johnsen, S. Rasheed, H. Makimura et al., TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J. Clin. Endocrinol. Metab. 96(1), E146–E150 (2011). https://doi.org/10.1210/jc.2010-1170
  16. A.B. Goldfine, R. Silver, W. Aldhahi, D. Cai, E. Tatro et al., Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin. Transl. Sci. 1(1), 36–43 (2008). https://doi.org/10.1111/j.1752-8062.2008.00026.x
  17. C.W. Shields, L.L.-W. Wang, M.A. Evans, S. Mitragotri, Materials for Immunotherapy. Adv. Mater. 32(13), e1901633 (2020). https://doi.org/10.1002/adma.201901633
  18. H.B. Eppler, C.M. Jewell, Biomaterials as tools to decode immunity. Adv. Mater. 32(13), e1903367 (2020). https://doi.org/10.1002/adma.201903367
  19. T.K. Kishimoto, R.A. Maldonado, Nanoparticles for the induction of antigen-specific immunological tolerance. Front. Immunol. 9, 230 (2018). https://doi.org/10.3389/fimmu.2018.00230
  20. K.L. Hess, I.L. Medintz, C.M. Jewell, Designing inorganic nanomaterials for vaccines and immunotherapies. Nano Today 27, 73–98 (2019). https://doi.org/10.1016/j.nantod.2019.04.005
  21. D. Zhao, W. Cui, M. Liu, J. Li, Y. Sun et al., Tetrahedral framework nucleic acid promotes the treatment of bisphosphonate-related osteonecrosis of the jaws by promoting angiogenesis and M2 polarization. ACS Appl. Mater. Interfaces 12(40), 44508–44522 (2020). https://doi.org/10.1021/acsami.0c13839
  22. Q. Zhang, S. Lin, S. Shi, T. Zhang, Q. Ma et al., Anti-inflammatory and antioxidative effects of tetrahedral DNA nanostructures via the modulation of macrophage responses. ACS Appl. Mater. Interfaces 10(4), 3421–3430 (2018). https://doi.org/10.1021/acsami.7b17928
  23. J.A. Baur, D.A. Sinclair, Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 5(6), 493–506 (2006). https://doi.org/10.1038/nrd2060
  24. S. Patra, B. Pradhan, R. Nayak, C. Behera, L. Rout et al., Chemotherapeutic efficacy of curcumin and resveratrol against cancer: Chemoprevention, chemoprotection, drug synergism and clinical pharmacokinetics. Semin. Cancer Biol. (2020). https://doi.org/10.1016/j.semcancer.2020.10.010 (In Press)
  25. T. Zhang, T. Tian, R. Zhou, S. Li, W. Ma et al., Design, fabrication and applications of tetrahedral DNA nanostructure-based multifunctional complexes in drug delivery and biomedical treatment. Nat. Protoc. 15(8), 2728–2757 (2020). https://doi.org/10.1038/s41596-020-0355-z
  26. S. Sirong, C. Yang, T. Taoran, L. Songhang, L. Shiyu et al., Effects of tetrahedral framework nucleic acid/wogonin complexes on osteoarthritis. Bone Res. 8, 6 (2020). https://doi.org/10.1038/s41413-019-0077-4
  27. T. Tian, D. Xiao, T. Zhang, Y. Li, S. Shi et al., A framework nucleic acid based robotic nanobee for active targeting therapy. Adv. Funct. Mater. 31(5), 2007342 (2020). https://doi.org/10.1002/adfm.202007342
  28. Y. Ge, T. Tian, X. Shao, S. Lin, T. Zhang et al., PEGylated protamine-based adsorbing improves the biological properties and stability of tetrahedral framework nucleic acids. ACS Appl. Mater. Interfaces 11(31), 27588–27597 (2019). https://doi.org/10.1021/acsami.9b09243
  29. J. Zhu, M. Zhang, Y. Gao, X. Qin, T. Zhang et al., Tetrahedral framework nucleic acids promote scarless healing of cutaneous wounds via the AKT-signaling pathway. Signal Transduct. Target. Ther. 5(1), 120 (2020). https://doi.org/10.1038/s41392-020-0173-3
  30. Y. Li, R. Zhou, D. Xiao, S. Shi, S. Peng et al., Polypeptide uploaded efficient nanophotosensitizers to overcome photodynamic resistance for enhanced anticancer therapy. Chem. Eng. J. 403, 126344 (2021). https://doi.org/10.1016/j.cej.2020.126344
  31. Y. Li, S. Wu, J. Zhang, R. Zhou, X. Cai, Sulphur doped carbon dots enhance photodynamic therapy via PI3K/Akt signalling pathway. Cell Prolif. 53(5), e12821 (2020). https://doi.org/10.1111/cpr.12821
  32. C.M. da Silva, M.M. Silva, F.S. Reis, A.L.T.G. Ruiz, J.E. de Carvalho et al., Studies on free radical scavenging, cancer cell antiproliferation, and calf thymus DNA interaction of Schiff bases. J. Photochem. Photobiol. B 172, 129–138 (2017). https://doi.org/10.1016/j.jphotobiol.2017.05.020
  33. M.S. Nair, A. Shukla, Molecular modeling, simulation and principal component analysis of binding of resveratrol and its analogues with DNA. J. Biomol. Struct. Dyn. 38(10), 3087–3097 (2020). https://doi.org/10.1080/07391102.2019.1662849
  34. J.M. Olefsky, C.K. Glass, Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 72, 219–246 (2010). https://doi.org/10.1146/annurev-physiol-021909-135846
  35. G.S. Hotamisligil, N.S. Shargill, B.M. Spiegelman, Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259(5091), 87–91 (1993). https://doi.org/10.1126/science.7678183
  36. G.S. Hotamisligil, P. Peraldi, A. Budavari, R. Ellis, M.F. White et al., IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271(5249), 665–668 (1996). https://doi.org/10.1126/science.271.5249.665
  37. H. Xu, G.T. Barnes, Q. Yang, G. Tan, D. Yang et al., Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112(12), 1821–1830 (2003). https://doi.org/10.1172/JCI19451
  38. C.N. Lumeng, A.R. Saltiel, Inflammatory links between obesity and metabolic disease. J. Clin. Invest 121(6), 2111–2117 (2011). https://doi.org/10.1172/JCI57132
  39. B.-C. Lee, M.-S. Kim, M. Pae, Y. Yamamoto, D. Eberlé et al., Adipose natural killer cells regulate adipose tissue macrophages to promote insulin resistance in obesity. Cell Metab. 23(4), 685–698 (2016). https://doi.org/10.1016/j.cmet.2016.03.002
  40. P. Tontonoz, B.M. Spiegelman, Fat and beyond: the diverse biology of PPARgamma. Annu. Rev. Biochem. 77, 289–312 (2008). https://doi.org/10.1146/annurev.biochem.77.061307.091829
  41. S. Schenk, M. Saberi, J.M. Olefsky, Insulin sensitivity: modulation by nutrients and inflammation. J. Clin. Invest. 118(9), 2992–3002 (2008). https://doi.org/10.1172/JCI34260
  42. M.C. Arkan, A.L. Hevener, F.R. Greten, S. Maeda, Z.-W. Li et al., IKK-beta links inflammation to obesity-induced insulin resistance. Nat. Med. 11(2), 191–198 (2005). https://doi.org/10.1038/nm1185
  43. R.A. DeFronzo, D. Tripathy, Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 32(Suppl 2), S157–S163 (2009). https://doi.org/10.2337/dc09-S302
  44. V.T. Samuel, G.I. Shulman, The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J. Clin. Invest. 126(1), 12–22 (2016). https://doi.org/10.1172/JCI77812
  45. A. Kalinkovich, G. Livshits, Sarcopenic obesity or obese sarcopenia: A cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis. Ageing Res. Rev. 35, 200–221 (2017). https://doi.org/10.1016/j.arr.2016.09.008
  46. S. Gordon, P.R. Taylor, Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5(12), 953–964 (2005). https://doi.org/10.1038/nri1733
  47. A. Mantovani, A. Sica, S. Sozzani, P. Allavena, A. Vecchi et al., The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25(12), 677–686 (2004). https://doi.org/10.1016/j.it.2004.09.015
  48. J. Zhong, X. Rao, Z. Braunstein, A. Taylor, V. Narula et al., T-cell costimulation protects obesity-induced adipose inflammation and insulin resistance. Diabetes 63(4), 1289–1302 (2014). https://doi.org/10.2337/db13-1094
Read More
Author biographies are not available.
Download this PDF file
PDF
Statistic
Read Counter : 4702 Download : 3553

Most read articles by the same author(s)

Similar Articles

You may also start an advanced similarity search for this article.